Literature DB >> 16418983

Risk factors and outcomes associated with non-Enterococcus faecalis, non-Enterococcus faecium enterococcal bacteremia.

Marie A de Perio1, Paul R Yarnold, John Warren, Gary A Noskin.   

Abstract

OBJECTIVES: To compare risk factors, clinical features, and outcomes in patients with Enterococcus avium, Enterococcus casseliflavus, Enterococcus durans, Enterococcus gallinarum, and Enterococcus mundtii bacteremia (cases) with those in patients with Enterococcus faecalis bacteremia (controls).
DESIGN: A retrospective case-control study.
SETTING: A 725-bed, university-affiliated, academic medical center. PATIENTS: The clinical microbiology database at Northwestern Memorial Hospital from January 1994 to May 2003 was searched to identify cases; each case was matched to one control on the basis of date of admission.
RESULTS: Thirty-three cases were identified and matched with 33 controls. The mean duration of hospital stay was longer (29.7 vs 17.2 days; P = .03) and the mean time to acquisition of bacteremia was greater (16.5 vs 6.3 days; P = .003) for cases than controls. Cases were more likely to have underlying hematologic malignancies (P < .001), to have been treated with corticosteroids (P = .02), and to be neutropenic (P = .003). Controls were more likely to have an indwelling bladder catheter (P = .01), and cases were more likely to have the gastrointestinal tract as a source of infection (P = .007) and to have concurrent cholangitis (P = .002). There were no differences in severity of illness or in mortality rates.
CONCLUSIONS: Compared with patients with E. faecalis bacteremia, patients with non-E. faecalis, non-Enterococcus faecium enterococcal bacteremia were more likely to have a hematologic malignancy, prior treatment with corticosteroids, neutropenia, and cholangitis; longer duration of hospital stay was also identified as a clinical feature. However, non-E. faecalis, non-E. faecium species are not associated with any differences in mortality.

Entities:  

Mesh:

Year:  2006        PMID: 16418983     DOI: 10.1086/500000

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  12 in total

Review 1.  Fatal Enterococcus durans aortic valve endocarditis: a case report and review of the literature.

Authors:  Rajakrishnan Vijayakrishnan; Alwyn Rapose
Journal:  BMJ Case Rep       Date:  2012-06-08

2.  Characterization of fecal vancomycin-resistant enterococci with acquired and intrinsic resistance mechanisms in wild animals, Spain.

Authors:  Carmen Lozano; David Gonzalez-Barrio; Maria Cruz Camacho; Jose Francisco Lima-Barbero; Javier de la Puente; Ursula Höfle; Carmen Torres
Journal:  Microb Ecol       Date:  2015-07-21       Impact factor: 4.552

3.  Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy.

Authors:  Graeme N Forrest; Mary-Claire Roghmann; Latoya S Toombs; Jennifer K Johnson; Elizabeth Weekes; Durry P Lincalis; Richard A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

Review 4.  The Enterococcus: a Model of Adaptability to Its Environment.

Authors:  Mónica García-Solache; Louis B Rice
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

5.  Clinical Features and Rate of Infective Endocarditis in Non-Faecalis and Non-faecium Enterococcal Bacteremia.

Authors:  Hee-Chang Jang; Wan Beom Park; Hong Bin Kim; Eui-Chong Kim; Myoung-Don Oh
Journal:  Chonnam Med J       Date:  2011-08-31

6.  Zebrafish as a novel vertebrate model to dissect enterococcal pathogenesis.

Authors:  Tomasz K Prajsnar; Stephen A Renshaw; Nikolay V Ogryzko; Simon J Foster; Pascale Serror; Stéphane Mesnage
Journal:  Infect Immun       Date:  2013-09-03       Impact factor: 3.441

7.  Novel Effective Small-Molecule Antibacterials against Enterococcus Strains.

Authors:  Kerolos Ashraf; Kaveh Yasrebi; Tobias Hertlein; Knut Ohlsen; Michael Lalk; Andreas Hilgeroth
Journal:  Molecules       Date:  2017-12-10       Impact factor: 4.411

8.  Vancomycin-Nonsusceptible Enterococci Mediated by vanC at a Large Children's Hospital: Prevalence, Susceptibility, and Impact on Care of Enterococcal Bacteremia.

Authors:  Daniel S Dodson; Samuel R Dominguez; Christine E MacBrayne; Manon C Williams; Sarah K Parker
Journal:  Open Forum Infect Dis       Date:  2020-05-06       Impact factor: 3.835

9.  Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia.

Authors:  Agnes Loo Yee Cheah; Trisha Peel; Benjamin P Howden; Denis Spelman; M Lindsay Grayson; Roger L Nation; David C M Kong
Journal:  BMC Infect Dis       Date:  2014-06-28       Impact factor: 3.090

10.  Superintendence of antimicrobial resistance observed in bacterial flora isolated from human faecal carriage in Vellore, India.

Authors:  Sundera Raj Esther Priyadharshini; Chidamabram Ramalingam; Balasubramanian Ramesh
Journal:  Saudi J Biol Sci       Date:  2015-11-24       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.